Tag: Types: HER2 positive breast cancer
News
- Age and breast cancer subtype influence prognosis after lumpectomy
- Alcohol promotes premenopausal HER2+ tumor development in a mouse model of HER2+ breast cancer
- Apigenin enhances the anticancer activity of 5-FU chemotherapy
- Apigenin increases effectiveness of Taxol chemotherapy
- Asian-American women have higher rates of HER2-positive breast cancer than Caucasians
- Black rice compound induces breast cancer cell death and and suppresses angiogenesis
- Blood type is not related to breast cancer outcomes
- BMI, type 2 diabetes, and breast cancer prognosis
- Breast cancer in old age
- Breast cancer prognosis - risk of locoregional recurrence by breast cancer subtype
- Breast cancer subtype influences prognosis after neoadjuvant chemotherapy
- Breast cancer type and survival statistics 1999-2004
- Capsaicin in hot peppers causes breast cancer cell death
- Change in HER2 status between primary and recurrence indicates poor prognosis
- Characteristics of breast cancer in women under 40
- Chemotherapy improves HER2+ and triple negative outcomes even for small (1cm) tumors
- Coexisting DCIS independently predicts lower tumor aggressiveness in luminal breast cancer
- Curcumin and DHA act synergistically in hormone receptor negative HER2+ breast cancer
- Diabetes accelerates tumor development in a mouse model of HER2+ breast cancer
- Different receptor status in lymph nodes might explain some treatment failures
- Does a family history of breast cancer increase the risk of certain subtypes?
- Effectiveness of MRI in monitoring effectiveness of chemotherapy depends on subtype
- Epidermal growth factor receptor (EGFR) expression associated with worse breast cancer prognosis
- ER negative, PR negative, and triple negative tumors have increased risk of locoregional recurrence
- Erythropoietin for anemia may hinder Herceptin treatment for HER2-positive breast cancer
- Fish oil reduces DNA damage, cell proliferation, and HER-2/neu expression in rats
- Flaxseed enhances Herceptin treatment in mouse model of HER2 breast cancer
- Follow-up after breast cancer should take into account risk of relapse
- Fucoidan in seaweed may prevent cancer by interfering with epidermal growth factor binding
- Herceptin has reduced locoregional recurrence for HER2+ compared to triple negative breast cancer
- Herceptin increases survival time for Stage IV HER2 breast cancer patients
- Herceptin plus anthracycline chemotherapy greatly increases risk of heart damage
- High C-reactive protein (CRP) levels linked to unfavorable breast cancer prognosis
- High intake of soy isoflavones increases risk of recurrence in HER2+ patients
- Hormone receptor status changes during progression in over one-third of breast cancer cases
- Knowing the receptor status of metastases improves treatment decisions
- Likelihood of late recurrence for hormone receptor positive breast cancer is hard to predict
- Low carbohydrate, high protein diet inhibits mammary tumor growth and development in mice
- Metformin improves survival of diabetic women with HER2+ breast cancer
- Non-anthracycline chemotherapy plus Herceptin is effective treatment for HER2+ breast cancer
- Oleic acid promotes breast cancer cell invasiveness
- Pomegranate compounds inhibit aromatase and reduces breast cancer cell proliferation
- Response to neoadjuvant chemotherapy depends on dosage and tumor type
- Risk of second primary breast cancer highest in hormone receptor negative survivors
- Survival times for metastatic breast cancer have been improving
- Treatment with Herceptin for one year improves survival in women with HER2+ breast cancer
- Turmeric component curcumin inhibits breast cancer cell proliferation